DE GREEF RODERICK 4
4 · BIOLIFE SOLUTIONS INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
BioLife (BLFS) CEO Roderick De Greef Receives Awards; Shares Withheld
What Happened Roderick De Greef, President, CEO and a director of BioLife Solutions (BLFS), received three restricted stock awards on Feb 24, 2026 totaling 508,045 shares (118,730 + 170,291 + 219,024). Concurrently, 153,196 shares were withheld to cover tax withholding obligations related to vesting (67,010 and 86,186 shares), at $22.65 per share, generating proceeds of $1,517,777 and $1,952,113 respectively (total $3,469,890). The awards were granted under BioLife’s 2023 Omnibus Performance Incentive Plan as part of 2026 compensation.
Key Details
- Transaction date: Feb 24, 2026; Form 4 filed Feb 26, 2026 (within typical 2-business-day reporting window).
- Awards received (code A): 118,730; 170,291; 219,024 shares — total 508,045 shares granted.
- Tax withholding (code F): 67,010 and 86,186 shares withheld and “disposed” from the reporting person's holdings at $22.65/share, netting $1,517,777 and $1,952,113 (total $3,469,890).
- Shares owned after the transactions: not specified in this filing.
- Footnotes: awards granted under the 2023 Plan. One award vests 25% after one year then quarterly (F1). One award vested at ~156% of the grant based on total shareholder return vs. peers (F2, F3). One award vested at 200% based on specific performance metrics (F4, F5). The withheld-share entries reflect tax withholding tied to those vestings.
Context These transactions are primarily grants of restricted stock that vested (including market- and performance-based vesting multipliers) and routine withholding of shares to satisfy tax obligations. Shares withheld for taxes are not open-market sales to a third party and are generally considered administrative — they do not necessarily indicate the insider is reducing economic exposure.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-24+118,730→ 508,728 total - Award
Common Stock
[F2]2026-02-24+170,291→ 679,019 total - Tax Payment
Common Stock
[F3]2026-02-24$22.65/sh−67,010$1,517,777→ 612,009 total - Award
Common Stock
[F4]2026-02-24+219,024→ 831,033 total - Tax Payment
Common Stock
[F5]2026-02-24$22.65/sh−86,186$1,952,113→ 744,847 total
Footnotes (5)
- [F1]The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.
- [F2]The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- [F3]Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
- [F4]The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the number of shares granted based on specific performance metrics of the registrant during the period beginning on January 1, 2024 through December 31, 2025.
- [F5]Represents shares withheld to cover tax withholding obligations in connection with the vesting of the performance-based restricted stock award.